Insider · CIK 0001962444
Matteo Levisetti
Files at CUE (Cue Biopharma, Inc.). First filing -, latest -.
Matteo Levisetti files SEC Form 4 as officer at CUE (Cue Biopharma, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Matteo Levisetti has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 29, 2025 | CUE CUE BIOPHARMA, INC. | 7,230 0.01% of outstanding | $1,907 | Dec 29, 2025 | none |
Transactions
Every row this insider has filed, 1 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 21, 2025 | CUE Cue Biopharma, Inc. | AGrant or award Stock Option (right to buy)derivative | +250,000 | $0.00 | $0 | 250,000 | Mar 25, 2025 |
Questions about Matteo Levisetti
Answered from the filings on this page, as of the latest one.
Is Matteo Levisetti buying or selling?
Matteo Levisetti has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Matteo Levisetti's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Matteo Levisetti has 0.
Where does Matteo Levisetti file Form 4?
Matteo Levisetti has filed Form 4 at CUE (Cue Biopharma, Inc.) as Chief Medical Officer. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.